Axsome Therapeutics (AXSM) Gains from Investment Securities (2015 - 2026)

Axsome Therapeutics has disclosed Gains from Investment Securities across 12 years of filings, most recently posting $6.6 million for Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at $6.6 million, up 2309.15% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.6 million (up 2309.15% YoY), and the FY2025 annual result was $7.0 million, down 16.65% from the prior year.
• Gains from Investment Securities came in at $6.6 million for Q1 2026 at Axsome Therapeutics, up from $1.0 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $9.2 million in Q1 2024 to a low of $38000.0 in Q4 2023.
• The 5-year median for Gains from Investment Securities is $900000.0 (2023), against an average of $2.4 million.
• Across the five-year window, Gains from Investment Securities plunged 97.97% in 2022 and soared 11360.53% in 2024, its largest moves.
• Axsome Therapeutics' Gains from Investment Securities stood at $163000.0 in 2022, then slumped by 76.69% to $38000.0 in 2023, then jumped by 11360.53% to $4.4 million in 2024, then sank by 76.03% to $1.0 million in 2025, then soared by 533.66% to $6.6 million in 2026.
• The last three Gains from Investment Securities figures came in at $6.6 million (Q1 2026), $1.0 million (Q4 2025), and $300000.0 (Q3 2025), per Business Quant data.